Posted in | News | Nanoanalysis

ACD's RNA Biomarker Analysis and Diagnostics Platform with Definiens' Image Analysis Technology to Advance Personalized Medicine in Oncology

Advanced Cell Diagnostics (ACD) has partnered with Definiens to create innovative image analysis software that will help scientists to precisely determine the quantity of distinct RNA molecules within single cells in a clinical sample.

The two firms will develop on the RNAscope platform of ACD and include specific image testing solutions that will autonomously process and assess images from RNAscope assays. The software will improve the usefulness of RNAscope-based investigative trials for custom-made medicine. The technology will be showcased by ACD at 2011 AACR conference, scheduled to be held in Orlando between April 3 and 6.

The RNAscope platform of ACD is an innovative and branded RNA in situ hybridization technique enabling identification and quantification of any expressed gene at individual molecule sensitivity in single cells in several sample types like cell lines, FFPE and PMBC tissue fragments. RNAscope facilitates the quickest path from genomic innovation to authorized biomarkers and clinical investigations.

As per the contract, novel and sophisticated image analysis software for ACD will be built by Definiens. The application will be developed from Definiens XD framework and will offer effective and expandable image analysis options for a broad range of histology investigations.

Thomas Heydler, CEO of Definiens, has stated that the collaboration between the two companies will enable the integration of two robust technologies in the emerging area of RNA biomarker recognition and development. He added that their high precision and multiplexing abilities of image intelligence technology will help ACD to develop robust RNA assays, supporting personalized medicine innovations globally.

According to Yuling Luo, Founder, President and CEO of ACD, their latest image analysis application will offer precise RNAscope quantification, enabling future investigative applications like recognition of moving cancer cells and molecular studies. He added that quantification of gene expression at the resolution of individual cell and subsequent analysis by pathologists within the perspective of histopathology has been performed for the first time.

Source: http://www.acdbio.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 12). ACD's RNA Biomarker Analysis and Diagnostics Platform with Definiens' Image Analysis Technology to Advance Personalized Medicine in Oncology. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=22119.

  • MLA

    Chai, Cameron. "ACD's RNA Biomarker Analysis and Diagnostics Platform with Definiens' Image Analysis Technology to Advance Personalized Medicine in Oncology". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=22119>.

  • Chicago

    Chai, Cameron. "ACD's RNA Biomarker Analysis and Diagnostics Platform with Definiens' Image Analysis Technology to Advance Personalized Medicine in Oncology". AZoNano. https://www.azonano.com/news.aspx?newsID=22119. (accessed November 21, 2024).

  • Harvard

    Chai, Cameron. 2019. ACD's RNA Biomarker Analysis and Diagnostics Platform with Definiens' Image Analysis Technology to Advance Personalized Medicine in Oncology. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=22119.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.